Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Aruba Science Wire.
Press releases published on August 6, 2025
Veeco Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
Second Quarter 2025 Highlights: Revenue of $166.1 million, compared with $175.9 million in the same period last year GAAP net income of $11.7 million, or $0.20 per diluted share, compared with $14.9 million, or $0.25 per diluted share in the same period …
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
GlobeNewswire
·
August 6, 2025
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, …
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a …
Sprout Social Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its second quarter ended June …
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
GlobeNewswire
·
August 6, 2025
First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with …
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
GlobeNewswire
·
August 6, 2025
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $303.4 million cash, cash …
electroCore Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
Net sales of $7.4 million increased 20% vs. Q2’2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025 Company to host a conference …
red violet Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
BOCA RATON, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter ended June 30, 2025. “We are pleased to report another strong …
Crane NXT Reports Second Quarter 2025 Results
GlobeNewswire
·
August 6, 2025
WALTHAM, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Crane NXT, Co. (NYSE: CXT) ("Crane NXT" or the "Company"), a premier industrial technology company, today announced its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 …
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
GlobeNewswire
·
August 6, 2025
Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a …
HilleVax Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Second …
Cerence Announces Third Quarter Fiscal 2025 Results; Revenue and Profitability Exceed High End of Guidance
GlobeNewswire
·
August 6, 2025
Headlines Revenue of $62.2 million; Net cash provided by operating activities of $23.7M; Free cash flow of $16.1 million marks fifth consecutive positive quarter Company raises and narrows full fiscal year guidance for revenue, adjusted EBITDA and free …
LiveRamp Announces Results for First Quarter FY26
GlobeNewswire
·
August 6, 2025
Revenue up 11% year-over-year Record-High Operating Margin for Q1 Share Repurchases totaled $30 million SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- LiveRamp® (NYSE: RAMP), a leading data collaboration platform, today announced its financial results …
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
GlobeNewswire
·
August 6, 2025
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and led to a meaningful …
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted EBITDA(1) of $50.8 Million, a 59% YoY Increase …
Senseonics Holdings, Inc. Reports Second Quarter Financial Results
GlobeNewswire
·
August 6, 2025
Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical …
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
GlobeNewswire
·
August 6, 2025
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further …
Snail, Inc. Sets Second Quarter 2025 Conference Call for Wednesday, August 13, 2025 at 4:30 p.m. ET
GlobeNewswire
·
August 6, 2025
CULVER CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will hold a conference call and webcast on …
Cytek Biosciences Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second …
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, …